Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients.

Journal of breast cancer

Lee Y, Park YR, Lee JS, Lee SB, Chung IY, Son BH, Ahn SH, Lee JW.
PMID: 30941236
J Breast Cancer. 2019 Mar 11;22(1):86-95. doi: 10.4048/jbc.2019.22.e14. eCollection 2019 Mar.

PURPOSE: Discontinuation of hormone therapy is known to lead to a poorer prognosis in breast cancer patients. We aimed to investigate the prescription gap as a prompt index of medication adherence by using prescription data extracted from patient electronic...

Cite
Lee Y, Park YR, Lee JS, et al. Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients. J Breast Cancer. 2019;22(1):86-95doi: 10.4048/jbc.2019.22.e14.
Lee, Y., Park, Y. R., Lee, J. S., Lee, S. B., Chung, I. Y., Son, B. H., Ahn, S. H., & Lee, J. W. (2019). Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients. Journal of breast cancer, 22(1), 86-95. https://doi.org/10.4048/jbc.2019.22.e14
Lee, Yura, et al. "Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients." Journal of breast cancer vol. 22,1 (2019): 86-95. doi: https://doi.org/10.4048/jbc.2019.22.e14
Lee Y, Park YR, Lee JS, Lee SB, Chung IY, Son BH, Ahn SH, Lee JW. Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients. J Breast Cancer. 2019 Mar 11;22(1):86-95. doi: 10.4048/jbc.2019.22.e14. eCollection 2019 Mar. PMID: 30941236; PMCID: PMC6438827.
Copy Download .nbib Format: NLM
Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists.

Current treatment options in cardiovascular medicine

Blaes AH, van Londen GJ, Sandhu N, Lerman A, Duprez DA.
PMID: 29707737
Curr Treat Options Cardiovasc Med. 2018 Apr 30;20(6):48. doi: 10.1007/s11936-018-0637-8.

PURPOSE OF REVIEW: The purpose of this review is to summarize the current literature on estrogen and progesterone antagonists and their effects on the cardiovascular system.RECENT FINDINGS: Estrogen and progesterone antagonists reduce cancer-related recurrence and mortality in women with...

Cite
Blaes AH, van Londen GJ, Sandhu N, et al. Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. Curr Treat Options Cardiovasc Med. 2018;20(6):48doi: 10.1007/s11936-018-0637-8.
Blaes, A. H., van Londen, G. J., Sandhu, N., Lerman, A., & Duprez, D. A. (2018). Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. Current treatment options in cardiovascular medicine, 20(6), 48. https://doi.org/10.1007/s11936-018-0637-8
Blaes, Anne H, et al. "Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists." Current treatment options in cardiovascular medicine vol. 20,6 (2018): 48. doi: https://doi.org/10.1007/s11936-018-0637-8
Blaes AH, van Londen GJ, Sandhu N, Lerman A, Duprez DA. Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. Curr Treat Options Cardiovasc Med. 2018 Apr 30;20(6):48. doi: 10.1007/s11936-018-0637-8. PMID: 29707737.
Copy Download .nbib Format: NLM
Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study.

International journal of women's health

Hervik J, Mjåland O.
PMID: 21151679
Int J Womens Health. 2010 Sep 28;2:319-25. doi: 10.2147/IJWH.S12809.

OBJECTIVE: The aim of this study was to examine the quality of life of breast cancer patients medicated with estrogen antagonists, 2 years after having acupuncture treatment for hot flashes.METHODS AND MATERIALS: Our sample was taken from women who...

Cite
Hervik J, Mjåland O. Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study. Int J Womens Health. 2010;2:319-25doi: 10.2147/IJWH.S12809.
Hervik, J., & Mjåland, O. (2010). Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study. International journal of women's health, 2319-25. https://doi.org/10.2147/IJWH.S12809
Hervik, Jill, and Mjåland, Odd. "Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study." International journal of women's health vol. 2 (2010): 319-25. doi: https://doi.org/10.2147/IJWH.S12809
Hervik J, Mjåland O. Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study. Int J Womens Health. 2010 Sep 28;2:319-25. doi: 10.2147/IJWH.S12809. PMID: 21151679; PMCID: PMC2990901.
Copy Download .nbib Format: NLM
Mechanisms for estrogen receptor expression in human cancer.

Experimental hematology & oncology

Hua H, Zhang H, Kong Q, Jiang Y.
PMID: 30250760
Exp Hematol Oncol. 2018 Sep 19;7:24. doi: 10.1186/s40164-018-0116-7. eCollection 2018.

Estrogen is a steroid hormone that has critical roles in reproductive development, bone homeostasis, cardiovascular remodeling and brain functions. However, estrogen also promotes mammary, ovarian and endometrial tumorigenesis. Estrogen antagonists and drugs that reduce estrogen biosynthesis have become highly...

Cite
Hua H, Zhang H, Kong Q, et al. Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol. 2018;7:24doi: 10.1186/s40164-018-0116-7.
Hua, H., Zhang, H., Kong, Q., & Jiang, Y. (2018). Mechanisms for estrogen receptor expression in human cancer. Experimental hematology & oncology, 724. https://doi.org/10.1186/s40164-018-0116-7
Hua, Hui, et al. "Mechanisms for estrogen receptor expression in human cancer." Experimental hematology & oncology vol. 7 (2018): 24. doi: https://doi.org/10.1186/s40164-018-0116-7
Hua H, Zhang H, Kong Q, Jiang Y. Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol. 2018 Sep 19;7:24. doi: 10.1186/s40164-018-0116-7. eCollection 2018. PMID: 30250760; PMCID: PMC6148803.
Copy Download .nbib Format: NLM
Isoflavones and bone: animal and human evidence of efficacy.

Journal of musculoskeletal & neuronal interactions

Chen X, Anderson JJ.
PMID: 15758427
J Musculoskelet Neuronal Interact. 2002 Jun;2(4):352-9.

Previous reports of soy extracts and isoflavone-enriched preparations studied in animals and humans have found that these molecules, when given at appropriate doses, have positive effects on the skeleton, including improvements in bone mineral content (BMC) and bone mineral...

Cite
Chen X, Anderson JJ. Isoflavones and bone: animal and human evidence of efficacy. J Musculoskelet Neuronal Interact. 2002;2(4):352-9
Chen, X., & Anderson, J. J. (2002). Isoflavones and bone: animal and human evidence of efficacy. Journal of musculoskeletal & neuronal interactions, 2(4), 352-9.
Chen, X, and Anderson, J J B. "Isoflavones and bone: animal and human evidence of efficacy." Journal of musculoskeletal & neuronal interactions vol. 2,4 (2002): 352-9.
Chen X, Anderson JJ. Isoflavones and bone: animal and human evidence of efficacy. J Musculoskelet Neuronal Interact. 2002 Jun;2(4):352-9. PMID: 15758427.
Copy Download .nbib Format: NLM
The in-vitro response of 4 antisteroid receptor agents on the hormone-responsive prostate-cancer cell-line lncap.

Oncology reports

Figg W, McCall N, Reed E, Sartor O.
PMID: 21597729
Oncol Rep. 1995 Mar;2(2):295-8. doi: 10.3892/or.2.2.295.

Previous reports indicate that flutamide withdrawal is associated with PSA declines and tumor shrinkage in selected patients with 'hormone-refractory' prostate cancer. Though the mechanisms underlying this effect are not clear, investigators have hypothesized that these effects are mediated by...

Cite
Figg W, McCall N, Reed E, et al. The in-vitro response of 4 antisteroid receptor agents on the hormone-responsive prostate-cancer cell-line lncap. Oncol Rep. 1995;2(2):295-8doi: 10.3892/or.2.2.295.
Figg, W., McCall, N., Reed, E., & Sartor, O. (1995). The in-vitro response of 4 antisteroid receptor agents on the hormone-responsive prostate-cancer cell-line lncap. Oncology reports, 2(2), 295-8. https://doi.org/10.3892/or.2.2.295
Figg, W, et al. "The in-vitro response of 4 antisteroid receptor agents on the hormone-responsive prostate-cancer cell-line lncap." Oncology reports vol. 2,2 (1995): 295-8. doi: https://doi.org/10.3892/or.2.2.295
Figg W, McCall N, Reed E, Sartor O. The in-vitro response of 4 antisteroid receptor agents on the hormone-responsive prostate-cancer cell-line lncap. Oncol Rep. 1995 Mar;2(2):295-8. doi: 10.3892/or.2.2.295. PMID: 21597729.
Copy Download .nbib Format: NLM
Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.

Breast care (Basel, Switzerland)

Thurner P, Nanoff C.
PMID: 21048911
Breast Care (Basel). 2008;3(6):401-406. doi: 10.1159/000172128. Epub 2008 Nov 25.

Adjuvant therapy improves survival in breast cancer patients. However, both antihormonal agents and cytostatic chemotherapy meet with variable success. We have searched the literature for biological causes of variability in drug response. Evidence suggests that additional markers may be...

Cite
Thurner P, Nanoff C. Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. Breast Care (Basel). 2008;3(6):401-406doi: 10.1159/000172128.
Thurner, P., & Nanoff, C. (2008). Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. Breast care (Basel, Switzerland), 3(6), 401-406. https://doi.org/10.1159/000172128
Thurner, Patrick, and Nanoff, Christian. "Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics." Breast care (Basel, Switzerland) vol. 3,6 (2008): 401-406. doi: https://doi.org/10.1159/000172128
Thurner P, Nanoff C. Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. Breast Care (Basel). 2008;3(6):401-406. doi: 10.1159/000172128. Epub 2008 Nov 25. PMID: 21048911; PMCID: PMC2931028.
Copy Download .nbib Format: NLM
Roles of prohibitin in growth control and tumor suppression in human cancers.

Translational oncogenomics

Wang S, Faller DV.
PMID: 21566741
Transl Oncogenomics. 2008 Feb 10;3:23-37.

Tumor formation results from alterations in the normal control of cell proliferation. In the past decade, much attention in cancer research has been focused on the function of proto-oncogenes and tumor suppressors. Prohibitin is a potential tumor suppressor which...

Cite
Wang S, Faller DV. Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics. 2008;3:23-37
Wang, S., & Faller, D. V. (2008). Roles of prohibitin in growth control and tumor suppression in human cancers. Translational oncogenomics, 323-37.
Wang, Sheng, and Faller, Douglas V. "Roles of prohibitin in growth control and tumor suppression in human cancers." Translational oncogenomics vol. 3 (2008): 23-37.
Wang S, Faller DV. Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics. 2008 Feb 10;3:23-37. PMID: 21566741; PMCID: PMC3022352.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries